Free Daily Podcast Summary
Molecule to Market: Inside the outsourcing space: Daily Summaries Delivered
by Raman Sehgal
Molecule to Market takes you inside the global pharma and biopharma outsourcing ecosystem. Each week, our host Raman Sehgal sits down with the founders, entrepreneurs, CEOs and C-suite leaders shaping the pharma services and tools that power discovery, drug development and commercialization. Listeners get real stories and practical insights from across the entire value chain, from big pharma and emerging biotechs to private equity investors, CROs, CDMOs, technology platforms and specialist consulting firms. Our host Raman is an entrepreneur, investor, bestselling author, speaker and long time industry insider.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 1 weeks ago1h 49m
M2M ENCORE: Zero to a billion… A CDMO original
In this special encore episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Thomas Eldered, Executive Chairman of Flerie. Your host, Raman Sehgal, revisits one of Molecule to Market’s most fascinating founder stories, bringing together Thomas’ original two part conversation into one episode charting the journey from a small Swedish contract manufacturer to a global CDMO powerhouse. Raman and Thomas discuss the pharmaceutical and biotechnology supply chain, covering: How a series of failed plans eventually led to the creation of a CMO before the term was widely used Building Recipharm from a local Swedish manufacturer into an international CDMO employing more than 9,000 people across 10 countries Why having cash during the financial crash created an opportunity to accelerate growth through M&A The decision to take Recipharm public when very few Swedish businesses, and virtually no CDMOs, were pursuing an IPO Why selling Recipharm after 26 years was one of the hardest decisions of his career How the divestment of Cobra Biologics led Thomas back into ownership, and how the gene therapy boom transformed the fortunes of the business Choosing passion rather than pension after his exits, and continuing to build and invest through Flerie The mindset, timing and calculated risk taking behind one of the most remarkable journeys in the CDMO sector Thomas Eldered co-founded Recipharm in 1995 and helped grow the company from a local Swedish contract manufacturer into one of the world’s leading CDMOs before leaving the business in 2021. He founded Flerie in 2011 and today serves as Executive Chairman. Flerie is a long term life science investor focused on developing companies built around scientific innovation and unmet medical needs. Thomas also serves as chairman and board member across a number of life science businesses. (Flerie) Thomas holds an MSc in Industrial Engineering and Management from Linköping University. Connect with him on LinkedIn. Molecule to Market is sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
- 2 weeks ago51 min
CPHI Milan Live: What matters more now?
Live from CPHI Milan, Molecule to Market and ramarketing bring together 11 senior leaders from across the global pharma outsourcing sector to tackle some of the industry's biggest trade-offs. In this special episode, produced in partnership with ramarketing, host Raman Sehgal cuts through the usual industry talking points with a series of rapid-fire, either-or questions designed to uncover what leaders are really prioritizing, where opinions align, and where perspectives differ. From balancing cost with flexibility to weighing technology against human expertise, we explore the decisions shaping the future of pharma services, what customers value most, and where the industry could be heading over the next five years. Expect different perspectives, some tough choices, and plenty of food for thought from the people helping shape the future of pharma outsourcing. Featuring insights from: Maja Pedersen, President and COO at Fujifilm Biotechnologies Hayley Crowe, Executive VP and General Manager of Global Life Sciences at Ecolab John Wichelt, VP/General Manager at Kindeva Henning Steinhagen, CEO at Symeres Campbell Bunce, Chief Scientific Officer at Abzena Patrick Kelley, Senior Director - Commercial at Pace Life Sciences Matt Peterson, Chief Strategy Officer at Quotient Sciences Joe Lipari, Director, Global Traceability Solutions at Systech Martin Meeson, CEO at Axplora Darren Hieber, VP of Alliance Partnerships at Ensera Pharma/Design Luke Guerrero, Co-Founder & Director of Operations at Digital CMC Consortium Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
- 3 weeks ago34 min
CPHI Milan Live Panel: The Real Truths Shaping Pharma Outsourcing
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with: Bobby Sheng, Chairman and CEO of Bora Pharmaceuticals Derek Hennecke, Biotech Entrepreneur and Board Member Maja Herold Pedersen, President and COO of Fujifilm Biotechnologies Your host, Raman Sehgal, discusses the real truths shaping pharma outsourcing with his guests live from CPHI Milan 2026. The event was hosted by Ramarketing and Molecule to Market. Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
- 4 weeks ago1h 22m
M2M ENCORE: Founding and Selling Three Bio CDMOs
In this special encore episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mark Bamforth OBE, serial entrepreneur, investor and mentor to CEOs. Your host, Raman Sehgal, revisits one of Molecule to Market’s most memorable conversations, bringing together Mark’s original two-part story of building and selling three biotech CDMOs for a combined value of $2.5bn. Raman and Mark discuss the pharmaceutical and biotechnology supply chain, covering: Mark’s unconventional journey from North Sea oil and the whisky industry to spending 22 years at Genzyme and ultimately leading a global manufacturing network. Leaving corporate life to build Gallus Biopharmaceuticals, and the baptism of fire that came with raising money for a self funded CDMO carve out. The strategy and timing behind Gallus and its eventual sale to Patheon. Spotting the opportunity in viral vectors early, and building Brammer Bio from start up to its $1.7bn acquisition by Thermo Fisher. Building Arranta Bio across microbiome, plasmid and mRNA capabilities, before an unsolicited approach led to its sale to Recipharm. Mark’s ability to spot where the market is heading, sometimes before conventional wisdom catches up. Leadership lessons from more than two decades at Genzyme and three successful founder to exit journeys. How he thinks about investing, mentoring CEOs and building businesses in complex, fast moving markets. Mark Bamforth OBE is a serial entrepreneur, investor and mentor to CEOs. He is currently CEO of disAMR, whose mission is to accelerate scientific, financial and policy solutions to protect modern medicine from antimicrobial resistant infections. He is also Executive Board Chair of Kincellis, an advanced therapies CDMO, General Partner of the Kineticos AMR Accelerator Fund, and serves on the boards of Enterobiotix, Continuus Pharma and the Saltire Foundation USA. Previously, Mark founded, built and sold three PE backed biotech CDMOs, Gallus Biopharmaceuticals, Brammer Bio and Arranta Bio, over a 12 year period for a combined value of $2.5bn. Before becoming an entrepreneur, Mark spent 22 years at Genzyme in the UK and US, latterly running a global manufacturing operation spanning 12 sites in nine countries and producing more than 20 commercial products. He began his career as a petroleum engineer exploring for North Sea oil with Britoil, before moving into the whisky industry as a chemical engineer with Whitbread. Mark holds a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College. He was appointed an Officer of the Order of the British Empire, OBE, for services to the biotech industry and UK USA business relations. Connect with him on LinkedIn. Molecule to Market is sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
- Sep 25, 202629 min
M2M SPECIAL: What Pharma Really Wants From Its CDMOs
In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector through the perspective of pharma-side buyers and external manufacturing leaders. Your host, Raman Sehgal, brings together insights from Daniel Hurni, Felipe Furiati, Frank Binder, and the buyer-side panel from CDMO Live Europe: When Outsourcing Goes Wrong, covering: What really goes into selecting a CDMO partner, and why price and technical capability are only part of the decision. Why product lifecycle, supply resilience, geography and risk all influence outsourcing strategy. What strong pharma-CDMO relationships look like in practice, including trust, transparency, governance and communication. Why being a genuine strategic partner requires much more than simply using the phrase. The early warning signs that an outsourcing relationship may be starting to fail, and why sponsors also need to take responsibility. What makes a CDMO stand out to experienced buyers, from consistency across sites to strong planning, risk management and operational capability. Why buyers increasingly want to understand the people and processes behind the equipment, not just the facility itself. This special episode brings together buyer-side perspectives from across Big Pharma, mid-sized pharma and global external manufacturing to provide CDMOs with a clearer view of what their customers really value. Molecule to Market is sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
- Sep 18, 202652 min
What Pharma really needs From CDMOs today
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Frank Binder, Independent Consultant (external manufacturing and supply chain management). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Frank, covering: Getting hooked on supply chain management during his time at Accenture, before joining Novartis’ biopharma business during the early stages of outsourcing and CDMO management. Deciding to move to Celgene, and feeling liberated by the hands-on, can-do culture of a fast growth company. The intrigue of joining a highly respected Japanese pharma company to help drive global supply chain alignment. Common themes in pharma and CDMO relationships, including better planning, clearer communication and secondary sourcing. How CDMO selection has evolved over the last 10 to 15 years, what has changed and what remains the same, including the role of regionalisation. The lens he uses to identify genuine, strategic partners he can trust. Dr. Frank Binder is a senior supply chain leader with experience across major pharmaceutical and biopharmaceutical companies in Switzerland, the US and Japan. He is now an independent consultant at GSCA | Global Supply Chain Advisors, having previously held senior roles at Santen, Celgene, Novartis, Roche and Accenture. His expertise spans global supply chain transformation, biologics and API production, CDMO management, international logistics, planning, NPI and SOP/IBP. Frank is a recognised pharmaceutical supply chain thought leader, regularly speaking at industry conferences across Europe, the US and Asia. He holds a doctorate in Physical Chemistry from the University of Berne, with further executive education at Cranfield University, Harvard Business School and INSEAD. Connect with him on LinkedIn. Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
- Sep 11, 202654 min
The CSO Staying Ahead of the CDMO Curve
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Stefan Randl, Chief Scientific Officer at Siegfried. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Stefan, covering: How his love of science, combined with a desire to get closer to the business, led him to leave Novartis His move from science into commercial roles, and how geographic relocations created a compound impact on his career The decision to leave a large pharma environment and join a smaller CDMO with both drug substance and drug product capabilities The importance of scientific innovation in creating competitive advantage in a busy and fragmented market Stefan’s role in shaping capability, R&D and technical investments, and why CDMOs must stay ahead of the curve by backing the areas they truly believe in How the need for accelerated speed to market is being driven by more assets, higher quality assets and increasingly complex products Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Stefan Randl (1973) joined Siegfried in January 2025 as Chief Scientific Officer. Prior to joining Siegfried, he spent 16 years at Evonik, where he held various leadership positions in several regions, most recently as Vice President Innovation Management Health Care, based in Frankfurt, Germany, and as Vice President Drug Substance, based in Indiana, US. He also headed Sales & Services for Health Care in Asia, based in Tokyo. He holds a PhD in Organic Chemistry from the Technische Universität Berlin and is a German citizen. Connect with him on LinkedIn.
- Sep 4, 202651 min
Leading a State Owned CDMO
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Erik Haeffler, CEO at APL. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Erik, covering: Two decades at AstraZeneca, including being at the forefront of global sourcing and increasingly sophisticated supply chain management in pharma Managing a highly complex network of more than 100 CDMOs during his time at Meda Lessons from six years at Recipharm, where he led 4,000 people across 14 manufacturing sites The unique story behind APL, what attracted him to the CEO role, and how his assumptions about a state owned business were challenged Implementing a clear strategy for APL’s CDMO business, leading to stronger differentiation and significant growth The decision to acquire a penicillin facility, and the growth engine now driving APL forward Erik leads APL, a Swedish pharma manufacturing company of 600 people across 5 sites. Being a state owned enterprise with a public policy assignment, APL is a bit of an odd bird on the pharma market. The state assignment comprises pharmacy compounding for the Swedish market, where APL has approx. 80% market share, and also a formal preparedness mission for supply in times of crisis and war. APL is also a fully commercial CDMO with a wide range of capabilities, focusing on a segment that fits into the company's origin in compounding. Erik has more than 30 years in the pharma industry with senior roles in AstraZeneca, Meda and Recipharm. He is also a Board member at Nanologica. Connect with him on LinkedIn. Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Get Molecule to Market: Inside the outsourcing space summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
MSL Talk
A podcast offering career and industry insights for Medical Science Liaisons, aspiring MSLs, and Medical Affairs professionals.
Fractional CMO Show
Casey Stanton
Sam Miller Science
Sam Miller
Bringing Chemistry to Life
Talks with leading chemists about their discoveries, careers, and the science shaping our world.
DGTL Voices with Ed Marx
Conversations with leaders and innovators driving digital transformation in healthcare.
The Home Service Expert Podcast
Home service business strategies from industry entrepreneurs and experts on growth, marketing, and scaling.
The Hunter Williams Podcast
Explores cutting-edge science in peptides, hormone optimization, and biohacking with experts pushing the limits of human performance.
My First Million
Two entrepreneurs analyze market trends and generate business ideas, often with guest collaborators.
Marketing Happy Hour
Real marketing career advice and strategies from industry pros, with honest conversations on growth, leadership, and balance.
Moonshots with Peter Diamandis
Exploring breakthrough technologies and their impact on humanity's future.
Everyone Hates Marketers | No-BS Marketing & Brand Strategy Podcast
A marketing podcast offering practical insights on branding, strategy, and customer research from industry professionals.
Get Better Faster
Doctors and researchers discuss functional medicine and root-cause approaches to chronic illness and health optimization.
About Molecule to Market: Inside the outsourcing space
Molecule to Market takes you inside the global pharma and biopharma outsourcing ecosystem. Each week, our host Raman Sehgal sits down with the founders, entrepreneurs, CEOs and C-suite leaders shaping the pharma services and tools that power discovery, drug development and commercialization. Listeners get real stories and practical insights from across the entire value chain, from big pharma and emerging biotechs to private equity investors, CROs, CDMOs, technology platforms and specialist consulting firms. Our host Raman is an entrepreneur, investor, bestselling author, speaker and long time industry insider.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Molecule to Market: Inside the outsourcing space in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Molecule to Market: Inside the outsourcing space daily summary?
It's a free AI-powered email that summarizes new episodes of Molecule to Market: Inside the outsourcing space as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Molecule to Market: Inside the outsourcing space podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Molecule to Market: Inside the outsourcing space product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Raman Sehgal.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
How often does Molecule to Market: Inside the outsourcing space release new episodes?
Molecule to Market: Inside the outsourcing space publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does Molecule to Market: Inside the outsourcing space cover?
Molecule to Market: Inside the outsourcing space covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Molecule to Market: Inside the outsourcing space summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.